Business
Science Corp raises $400M at a reported $3.5B to bring its PRIMA vision implant to the US. What to watch
Max Hodak's brain-computer interface company closed a $400 million Series D, eight months after a $230 million Series C. The money is meant to take PRIMA, a retinal implant already CE-marked in Europe, to the US through the FDA's Humanitarian Device Exemption route, a narrower path than full approval.